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ABSTRACT:  We aimed to analyze the diagnostic accuracy of an automated segmentation and 
quantifica-tion method of the SNc and locus coeruleus (LC) volumes based on neuromelanin (NM)-
sensitive MRI (NM-MRI) in patients with idiopathic (iPD) and monogenic (iPD) Parkinson’s disease (PD). 
Thirty-six patients (23 idiopathic and 13 monogenic PARKIN or LRRK2 mutations) and 37 age-
matched healthy controls underwent 3T-NM-MRI. SNc and LC volumetry were performed using fully 
automated multi-image atlas segmentation. The diagnostic performance to differentiate PD from 
controls was measured using the area under the curve (AUC) and likelihood ratios based on receiver 
operating characteristic (ROC) analyses. We found a significant reduction of SNc and LC volumes in 
patients, when compared to controls. ROC analysis showed better diagnostic accuracy when using 
SNc volume than LC volume. Significant differences between ipsilateral and contralateral SNc 
volumes, in  relation  to  the  more                                             clinically affected side, were found in patients with iPD (P 5 0.007). 
Contralateral atrophy in the SNc showed the highest power to discriminate PD subjects from controls 
(AUC, 0.93-0.94; sensitivity, 91%–92%; specificity, 89%; positive likelihood ratio: 8.4-8.5; negative 
likelihood ratio: 0.09-0.1 at a single cut-off point). Inter-val likelihood ratios for contralateral SNc 
volume improved the diagnostic accuracy of volumetric measurements. SNc and LC volumetry based 
on NM-MRI resulting from the automated segmentation and quanti-fication technique can yield high 
diagnostic accuracy for differentiating PD from health and might be an unbiased disease biomarker.
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diagnosis
Funding agencies: Supported by the Fund for Health Research Foundation (FIS-ISCIII), Spanish Ministry of Economy and Competitiveness (reference: PI
13/02211); Spanish Ministry of Science and Innovation SAF2006-10126 (2006-2009), SAF2010-22329-C02-01 (2011-2013), and SAF2013-47939-R (to
P.P.); project 061131 from the “Fundacio La Marato de TV3” and by the UTE project FIMA, Spain (to P.P.). C.O.d.S. and A.M.B. were supported by
Spanish Ministry of Economy and Competitiveness DPI2012-38090-C03-02 and TEC2013-48552-C2-1-R, respectively.
Relevant conflicts of interest/financial disclosures: M.A.P. has been also funded by CIBERNED, Centro de Investigacion Biomedica en Red de Enfer-
medades Neurodegenerativas, Instituto de Salud Carlos III, Madrid, Spain and by the UTE project FIMA, Spain. There are no conflicts of interest.
1
*Correspondence to: Dr. Marıa A. Pastor, Center for Applied Medical Research, University of Navarra, Pio XII, 55, 31008 Pamplona, Spain; mapastor@unav.es
yAuthors M.A.P. and P.P. contributed equally to the study.
Parkinson’s disease (PD) is a neurodegenerative dis-
order characterized by asymmetrical bradykinesia, rest
tremor, and rigidity. Loss of neuromelanin (NM)-con-
taining neurons in the SNc and locus coeruleus (LC) is
characteristic in early PD stages.1,2 Thus, in vivo iden-
tification of underlying SNc and LC degeneration
based on NM-sensitive MRI (NM-MRI)3-7 may help
in the diagnosis of PD.
There are no validated MRI biomarkers to quantify
the brainstem PD neurodegeneration,8,9 and accurate
manual segmentation of brainstem nuclei is indeed diffi-
cult owing to their irregular morphological characteris-
tics.6,9 Multi-image atlas-based segmentation is a
promising approach given that it accounts for the inter-
subject variability to obtain reliable segmentations.10
Neuropathological reports of patients with LRRK2
and PARKIN mutations show marked neuronal loss
in the SNc and LC, as observed in idiopathic PD
(iPD).11 The accuracy of the clinical diagnosis of PD is
highly variable and genetic forms are relatively rare,
thus the postmortem examination still remains the
gold standard to confirm the diagnosis of PD. There-
fore, we hypothesized that the inclusion of more
homogeneous groups, such as PD subjects with mono-
genic forms, could help to identify the characteristic
NM-pigmented cell loss in iPD.
We aimed to analyze the diagnostic accuracy of an
NM-MRI-based completely automated method for
segmentation and quantification of SNc and LC vol-
umes for differentiating healthy subjects from PD
patients previously screened for the most common PD
genes in our population (LRRK2 and PARKIN). We




The inclusion criterion for the patients was that they
had been diagnosed with probable PD by a movement
disorders specialist according to the UK Brain Bank
criteria.12 Clinical data, such as dexterity and disease
duration, were obtained. The clinically most affected
side was recorded as left, right, or bilateral when the
patient reported an asymmetric onset of motor symp-
toms or a predominantly affected side. PD subjects
were assessed taking their current dopaminergic treat-
ment with the UPDRS-III being in the ON state. We
excluded subjects with a Mini–Mental State Examina-
tion score (MMSE) <24/30, PD H & Y staging IV,
subjects with substantial head movements at rest,
claustrophobia, history of DBS, and medical or perso-
nal conditions that prevented the subject from under-
going an MRI exam.
Age-matched unrelated healthy subjects and spouses
of affected PD subjects were recruited in the same
center and from the community. Subjects suffering
from a neurological disorder or with a positive family
history of neurodegenerative disease were excluded.
Clinical assessment and MRI scanning were performed
on the same day. Written informed consent was
obtained from every participant and the institutional
ethics research review board approved the study. In
order to classify PD patients according to their genetic
background, all patients were genotyped for LRRK2
and PARKIN mutations (Supporting Table 1).
MRI Scanning Protocol
All scans were performed in a 3-T Trio TIM MR
scanner (Siemens, Erlangen, Germany), using a 12-
channel head array. Images of the brainstem were
obtained with an NM-sensitive imaging sequence,
modified from a T1-weighted fast spin-echo sequence,
as described previously,3 to achieve a slightly higher
resolution with the following parameters: repetition
time/echo time, 600/15 ms, two-echo train length, 11
slices, 2.0-mm slice thickness, 0.2-mm gap, 512 3 408
acquisition matrix, field of view, 220 3 175 mm2
(pixel size 0.43 3 0.43 mm2, interpolated to 0.21 3
0.21 mm2), bandwidth 110 Hz/pixel, four averages,
and total scan time of 12 minutes (Supporting Infor-
mation). Slices were perpendicularly oriented toward
the fourth ventricle floor, using a previously acquired
sagittal localizer and covered from the posterior com-
missure to the pons.
Automated Volume Measurements of NM-MR 
Images
NM-pigmented regions were automatically
delineated (Fig. 1) using a reference atlas composed of
13 manually segmented NM-MR images10 (Supporting
Information). We calculated the segmentation accu-
racy and used a modified approach from two previous
studies4,6 to quantify the SNc and LC volumes (Sup-
porting Information).
Statistical Analyses
Nonparametric receiver operating characteristic
(ROC) curves were constructed for each group of
patients and control subjects using the clinical diagno-
sis as the “gold standard.” Then, logistic regression
was used to estimate the effect of adding the LC vol-
ume to the contralateral SNc volume measurements
on the classification accuracy. Given that a single opti-
mal cut-off point varies depending upon the calcula-
tion method employed and its associated costs,13,14 we
calculated the sensitivity, specificity, and classification
accuracy of more than one selected cut-off point on
the nonparametric ROC curves of patients with iPD
and applied these cut-off points to the SNc volume
measurements of all PD patients combined. In
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addition, the positive and negative likelihood ratios
(LR1, LR–) associated with the highest classification
accuracy were computed. Using the same cut-off
points, we constructed three categories as well as
interval likelihood ratios (iLRs). iLRs have been sug-
gested to assess the diagnostic value of tests with
continuous measurements because they provide more-
useful information.15-17 We selected the optimal cut-
off points by the ROC convex hull method
(ROCCH).18 Statistical analyses were performed using
Stata software (12.0; StataCorp LP, College Station,
TX) (Supporting Information).
Results
Demographic and Clinical Data
Thirty-six PD patients and 37 healthy subjects were
recruited (Table 1). Thirteen (36%) patients showed a
TABLE 1. Demographic and clinical characteristics of the study groups
Characteristics HS (n537) iPD (n5 23) PD LRRK2 (n5 8) PD PARKIN (n5 5) P Value*
No. female/male 18/19 5/18 3/5 3/2 0.28a
Age, years 62 (52-70) 65 (55-70) 73 (67-75) 48 (47-67) 0.08
Handedness, right/left 37/0 22/1 7/1 5/0 NA
Most affected side, right/left/bilateral NA 11/12/0 5/2/1 0/4/1 NA
Disease duration, years NA 6 (3-8) 9 (7-10) 29b,c(18-30) <0.001
UPDRS-III Score NA 13 (6-18) 12 (6-20) 19 (18-22) 0.07
MMSE Score 29 (28-30) 28 (27-29) 28 (25-29) 28 (25-30) 0.06
Data are presented as number or median (interquartile range).
*Kruskal-Wallis’ test.
aFisher’s exact test.
bP50.03 (PARKIN vs. LRRK2).
cP5 0.004 (PARKIN vs. IPD).
HS, healthy subjects; PD LRRK2, LRRK2 PD heterozygous mutation carriers; PD PARKIN, PARKIN PD mutation carriers; Disease duration, duration of motor
symptoms for the more affected body side; UPDRS-III5UPDRS-motor scale; NA5not applicable.
FIG. 1. NM-MRI showing the automatically segmented regions of interest (ROIs). SNc and LC of a healthy subject (A). Three-dimensional surface
rendering corresponding to automated segmentation of the bilateral SNc and LC (B). NM-MRI of a patient with iPD with 4 years of motor symptom
duration (C). NM-MR images of the SNc and LC (first column). ROIs detected in the automated segmentation with the brainstem background area
shown in blue (second column). Hyperintense pixels of the SNc and LC above the threshold (third column).
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monogenic cause (5 patients carried mutations in the
PARKIN gene and 8 in the LRRK2 gene; Supporting
Table 1). For the purpose of the study, patients were
grouped in three categories based on LRRK2/PARKIN
mutation status: (1) iPD; (2) combined LRRK2 G2019S,
R1441G, and R1761S carriers; and (3) combined PAR-
KIN homozygotes and compound heterozygote.
Overall, 60% of the participants were male, but
sex distribution did not significantly differ among the
groups. A total of 34 (94%) patients reported an
asymmetrical clinical course, affecting either the right
or left side in 16 (44%) and 18 (50%) patients,
respectively. Patients with LRRK2 mutations were
predominantly affected on the right side (5 of 8) and
patients with PARKIN mutations on the left side (4
of 5). Median duration of motor symptoms in the
total group of patients was 7 years. Although patients
with PARKIN mutations had lower median age and
higher median UPDRS-III scores, the differences
between groups were not significant. The only statis-
tically significant difference observed was the fact
that PARKIN patients had an earlier age of onset
and a longer duration of motor symptoms than the
other groups (Table 1).
NM Imaging
Total SNc and LC volumes were significantly
reduced in iPD patients and in those with LRRK2 and
PARKIN mutations, when compared to controls, and
ROC curves indicated good classification performance
for both markers and different thresholds (Table 2
and Supporting Table 2; Supporting Fig. 4). These
measures demonstrated, on the one hand, similar dis-
criminating power for both markers in patients with
mutations and high discriminating power for identifi-
cation of those with PARKIN mutations. On the other
hand, the SNc showed better diagnostic accuracy than
LC volume in iPD patients. In contrast, in a post-hoc
analysis, we did not detect significant differences
between patient subgroups.
When ipsilateral and the contralateral SNc volumes
with reference to the clinically more affected side were
compared (Fig. 2; Supporting Table 3), contralateral
SNc volume was significantly reduced in patients with
iPD by a mean difference of 12.8 mm3 with respect to
the ipsilateral side (95% confidence interval
[CI]5 3.9-21.7 mm3; paired t test: t52.97; df5 22;
Hedges’s g5 0.50; P50.007), but the differences did
not reach statistical significance in monogenic PD
(mPD) patients (mean difference511.9 mm3; 95%
CI520.5 to 24.5 mm3; paired t test: t5 2.13;
df510; Hedges’s g5 0.37; P50.059). In the ROC
analyses, higher AUCs for the contralateral SNc and
TABLE 2. Bilateral volume measurements in the SNc and LC and comparisons between groups
Parameters HS (n5 37) iPD (n523) PD LRRK2 (n5 8) PD PARKIN (n5 5)
SNc volumea, mm3 248.2 (214.3-284.6) 155.5 (124.5-188.9) 162.8 (127.8-205.6) 122.5 (108.3-126.0)
P< 0.001b P5 0.005b P5 0.002b
AUC5 0.91 AUC5 0.86 AUC5 0.97
(0.82-0.97) (0.61-0.98) (0.89-1.00)
LC volumea, mm3 15.2 (13.2-19.6) 11.9 (9.0-15.5) 10.4 (7.9-13.0) 8.2 (7.7-11.0)
P5 0.019b P5 0.002b P5 0.004b
AUC5 0.73 AUC5 0.88 AUC5 0.95
(0.58-0.86) (0.72-0.96) (0.84-1.00)
Data are presented as median (interquartile range).
aP5<0.001, comparison between all groups using Kruskal-Wallis’ test.
bCompared with HS using the nonparametric Steel test.
HS, healthy subjects; PD LRRK2, LRRK2 PD heterozygous mutation carriers; PD PARKIN, PARKIN PD mutation carriers; AUC, area under the ROC curve.
FIG. 2. Bar chart comparing the SNc volume measurements on NM-
MRI in healthy subjects and groups of patients. Comparison of ipsilat-
eral and contralateral SNc volume measurements in patients with iPD
(n523) and in those with mPD (n5 11). Bars represent mean and
error bars represent standard deviation. Volume contralateral to the
clinically affected side was computed for patients with asymmetric
disease and mean SNc volumes in the case of healthy subjects or
patients with symmetric disease.
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similar AUCs for patients with iPD and for all patients
combined (Supporting Table 3; Supporting Fig. 9).
Correlation analyses of total SNc or LC volumes with
age, disease duration, UPDRS-III, or MMSE scores
yielded no significant associations in any of the groups,
nor correlation between SNc and LC volume changes.
In the regression analysis considering all PD patients,
age, sex, and clinical disease duration significantly pre-
dicted a reduction of SNc volume contralateral to the
clinically predominantly affected side (F3,3254.1;
P5 0.01; R25 0.16), but only disease duration was sig-
nificantly associated (b520.99; 95% CI521.69 to
20.28; t(36)522.87; P5 0.007). Despite this associa-
tion, the results of parametric ROC analyses showed no
significant influence of age, sex, or disease duration on
the ROC curve, with an adjusted AUC of 0.93 (95%
CI50.84-1.00), similar to the uncorrected model, which
suggests that the power to discriminate between controls
and PD patients tends to remain relatively stable across
different disease durations. Addition of the LC volume
to the contralateral SNc volume in a logistic regression
model increased the AUC to 0.95 (Supporting Fig. 9).
ROC analysis showed that the best classification accu-
racy (90%) was obtained with a cut-off point of
103.1 mm3 volume in the SNc, which resulted in high sen-
sitivities and specificities in patients and controls (Table
3). With the SNc volume measurements dichotomized at
this cut-off point, the LR1 of a decrease in the volume was
higher than 8 and the LR– lower than 0.1. To further
explore the possible diagnostic utility of SNc volume
quantification, we calculated the iLRs for SNc volume
measurements for iPD and all PD patients combined
(Table 3). As expected, lower SNc volume measurements
were associated with greater LRs (>20) and higher SNc
volume measurements with lower LRs (<0.05). Intervals
with higher and lower SNc volumes showed more inform-
ative LRs than LRs obtained using a single cut-off value.
Discussion
This study aimed to establish the diagnostic accu-
racy of quantification of structural brainstem changes
in iPD and mPD using a T1-weighted NM-MRI
optimized technique. The results of our study showed
that the degree of SNc atrophy, measured using a fully
automated quantification technique based on the NM-
MR images, and especially the contralateral SNc vol-
ume to the most clinically affected side, had high dis-
criminatory power to differentiate healthy subjects
from patients with PD. This suggests that this measure
has potential diagnostic utility in clinical settings, as
well as for future studies including both idiopathic
and monogenic forms of PD.
Our results are in agreement with previous NM-
MRI studies in iPD with manual or semiautomatic
segmentation methods, which have consistently
reported significant reductions in measures of voxel
intensity, area, and volume of total SNc and LC.3-7
We found higher diagnostic accuracy of the mean
bilateral SNc at a single cut-off point when discrimi-
nating between PD patients and control subjects than
previous NM-MRI studies,6,7 possibly as a conse-
quence of our fully automated volumetric method,
suggesting that these assessments may have a potential
diagnostic value. One previous study concluded that
quantification of hyperintense pixels better reflects pig-
ment content and was a more sensitive method.4 Fur-
thermore, owing to the asymmetrical nature of PD19
and in vivo irregular morphological characteristics of
these regions,20 we modified previously proposed
methods4-6 and improved the quantification of hyper-
intense pixels by calculating an optimal threshold and
by using an automated method. This allowed us to
find not only significant total SNc and LC volume
reductions, but also a reduction of the contralateral
SNc volume relative to the clinically most affected
side.
The ipsilateral versus contralateral SNc volume dif-
ferences found in our study are in line with neuropa-
thologic data21 and also with previous neuroimaging
studies, which have found asymmetries of the nigro-
striatal system in patients with idiopathic and mono-
genic PD.19,22-24 Previous MRI studies in PD have
reported significantly lower T1 relaxation times25 and
higher iron deposition26 in the contralateral SN to the
most affected side, but not nigral atrophy. The
TABLE 3. Accuracy measures for contralateral SNc volume in PD patients
Cutoff (mm3) No. of HS Patients with iPD (n5 23) All PD patients (n5 36) LR IPD LR All PD patients











<72.1 1/37 13/23 21/36 20.9 (3.1-160) 21.6 (4.8-124.8)
72.1-106.1 7/37 10/23 14/36 2.3 (1.03-5.7) 2.1 (0.97-4.52)
>106.1 29/37 0/23 1/36 0 0.035 (0.006-0.18)
Single5 cut-off point at the level with highest classification accuracy (90%). The number of subjects with an SNc volume falling into each level is shown. Data
in parentheses are 95% CIs. The interval LR is the probability of the defined volume interval when PD is present divided by the probability of the same volume
interval when the disease is absent. The intervals were constructed from optimal cut-off points defining the convex hull of the ROC curve in iPD patients.
HS, healthy subjects; AUC, area under the ROC curve.
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diagnostic accuracy of the ipsilateral SNc volume mea-
surement was similar to previous studies using manual
or semiautomatic segmentation methods, but the con-
tralateral volume showed higher power to discriminate
PD subjects from controls. However, differences in
image acquisition parameters, image processing, ROI
selection methods, and clinical characteristics of
patients hinder the quantitative comparison of NM-
MRI studies. We also found that quantifying the LC
volume could have a small added value in the discrim-
inatory ability of the measures, which adds new infor-
mation to the findings established by previous
work.3,4,7,27
Other advanced techniques, such as relaxometry,28
diffusion tensor imaging (DTI),27,29 and susceptibility-
weighted imaging (SWI),30 are capable of identifying
brainstem nuclei changes and have been proposed as
imaging biomarkers in PD.9 Manual or semiautomatic
identification of the SN and LC and voxel-wise meth-
ods have been used to characterize the amount and
direction of water diffusion in affected tissues on DTI
images and the amount of iron deposition with relax-
ometry and SWI images. One study using NM-MRI
and DTI showed LC changes in PD patients with rapid
eye movement sleep behavior disorder (RBD),27 but to
date, no direct studies have been performed that com-
pare the accuracy for PD diagnosis between NM-MR
imaging and these different imaging methods.
The first advantage of NM-MRI over other MRI
techniques is that it allows a better delineation of the
SNc, given that the hyperintense signal area correlates
with NM-containing neuron density as described in a
NM-MRI postmortem case study.31 Second, detecting
the atrophy of the contralateral SNc to the most clini-
cally affected side may allow earlier diagnosis, as has
been suggested by recent longitudinal PET studies.32,33
Finally, other studies showed that NM-MRI may also
help in detecting specific PD subgroups, such as
patients with RBD,27 and in distinguishing PD from
atypical parkinsonian syndromes.34,35
It has been reported that the PD presymptomatic
neurodegenerative process lasts for 2 to 40 years.2,32
When the pathological process reaches the pontine
tegmentum, between Braak’s stages 2 and 4, loss of
pigmented neurons has been observed in the SNc and
the LC, further increasing in later stages.2 Although
the affection of the LC cells precedes that of the SNc,
we found higher discriminative power for the SNc
than LC in patients with iPD, which could be the
result of insufficient imaging resolution or higher vul-
nerability of NM-pigmented neurons of the SNc, com-
pared with the LC, as has been observed in
postmortem studies.1,11,36,37 We also corroborated
postmortem studies in PD LRRK2 and PARKIN
mutation carriers,11 finding significant differences in
monogenic patients when compared to controls.
Early diagnosis of PD is often difficult and diagnos-
tic accuracy ranges between 26% and 90% and
improves as a function of expertise, medication
response, and disease duration.38-40 Genetic analysis is
a tool to predict accurately underlying pathology in
patients. In our patients, median disease duration was
7 years (range, 1-33), and, although disease duration
was longer in patients with PARKIN mutations and
was associated with the SNc volume reduction in the
total group of patients with PD, we were not able to
detect any effect of disease duration on the discrimi-
nating power of the regression models. Previous cross-
sectional NM-MRI4,5 and PET41 studies described
similar levels of linear correlation with disease dura-
tion, and a recent study42 showed no significant differ-
ences in total neuronal density of the SNc, despite
differences in disease duration, between PARKIN and
iPD. The small effect of the disease duration may be
explained by the nonlinear pattern of nigral cell loss
described in longitudinal PET studies,22 the high inter-
individual variability described in postmortem volu-
metric studies,43-45 and also by a recent postmortem
study in iPD that described a highly variable reduction
(33%–80%) in SNc-pigmented cells in the first 7 years
postdiagnosis with a slower, less variable rate of
degeneration after 10 years of disease progression.46
In our study, the iLRs calculated on the SNc volume
values divided into three levels produced more useful
clinical information than when dichotomized and
could potentially overcome the limitations of deriving
a single threshold on a continuous measurement.14-17
LRs reflect how many times more likely a measure-
ment level is in patients, in comparison to control sub-
jects, and, in our study, a contralateral volume lower
than 72.1 mm3 was approximately 20 times more
likely to belong to a PD patient than to a control sub-
ject. Conversely, a volume higher than 106 mm3 was
approximately 20 times more likely to belong to a
control than to a patient. We suggest that deriving
iLRs can improve the diagnostic utility of SNc volu-
metric analyses in future studies and contribute to the
incorporation of quantitative NM-MRI test as a clini-
cal diagnostic tool to help predict the probability of
PD on an individual patient basis.16,47
To improve volumetric accuracy, we used higher
spatial resolution than previous NM-MRI studies and
we attempted to correct for motion artefacts by
acquiring separate averages, repeating motion-
corrupted acquisitions, and combining them offline
after motion correction. Finally, we used an unbiased
automated method for segmentation as well as a more
sensitive method for quantification. The advantage of
using automated over manual segmentation is that it
allows us to measure the volume of the SNc and LC
with high reliability and objectivity, thus eliminating
interoperator variability, which is especially useful in
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studies with a large cohort of subjects, as well as lon-
gitudinal and multisite studies. Specifically, using a
multi-image atlas in the segmentation process incorpo-
rates intersubject variability in the segmentation,
which, in turn, provides accurate results in heterogene-
ous populations. One other strong point of our study
is that we accurately assessed the mutation status of
patients, which improved the confidence in the rela-
tionship between the etiological diagnosis and the neu-
roimaging findings.
The first limitation is that NM-MR imaging typi-
cally uses low spatial resolution in the slice direction
that also suffers partial volume effect and insufficient
coverage, which may result in inaccurate volume cal-
culations and lower segmentation accuracy in PD
patients, especially in the LC, possibly owing to its
smaller volume. As a consequence of the spatial reso-
lution or the sample size of each patient group, we
could not detect significant differences between idio-
pathic and genetic PD. Nevertheless, we were able to
detect significant differences, when compared to con-
trols, and our data are in agreement with postmortem
and with other neuroimaging studies of patients with
idiopathic and monogenic PD. Other limitations of
our study are its cross-sectional design, the lack of
autopsy data supporting the accuracy of our imaging
methodology, and, because no disease controls were
examined, the specificity of our findings to the differ-
ential diagnosis could not be determined. Finally, and
as previously discussed, another potential limitation is
the significant difference in disease duration between
the patient groups. Further studies with a higher sam-
ple size and improved technique, in more specific sub-
groups such as patients with RBD27 and psychiatric
disorders,48 will be required to acknowledge these
limitations.
In? conclusion,? using? automated? quantification?of?
the? contralateral? SNc? atrophy? and?LR-based? statisti-
cal?methods,?we? found? high? discriminatory? accuracy?
between? patients? with? PD? and? healthy? subjects,?
which? may? offer? good? diagnostic? value? in? clinical?
settings? and? for? the? design? of? future? clinical? trials.?
Degeneration? of? melanized? neurons? is? an? important?
pathological? hallmark? associated? with? the? motor?
signs? of? PD,? and? so? NM-MRI-related? measures? are?
biomarkers? that? could? contribute? to? improve? the?
diagnostic? accuracy? of? the? disease,? as? well? as? help?
toward? a? better? understanding? of? the? heterogeneous?
clinical?and?pathological?characteristics?of? idiopathic?
and? monogenic? PD.? Ultimately,? defining?t he?appro-
priate? role? for?NM-MR? imaging? in? the?diagnosis?and?
management? of? PD?will? require? additional? studies? in?
order? to? further? develop? the? method? for? future?
cohort? studies? including?asymptomatic?mutation?car-
riers? and? patients? with? idiopathic? and? monogenic?
PD.
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